Cigna®

Fax completed form to: (855) 840-1678
If this is an URGENT request, please call (800) 882-4462
(800.88.CIGNA)

Tecentriq Hybreza

(atezolizumab and hyaluronidase-tqjs)

PHYSICIAN INFORMATION			PATIENT INFORMATION		
* Physician Name:			*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this form are completed.*		
Specialty:	* DEA, NPI or TIN:				
Office Contact Person:			* Patient Name:		
Office Phone:			* Cigna ID:	* Date of Birth:	
Office Fax:			* Patient Street Address:		
Office Street Address:			City:	State:	Zip:
City:	State:	Zip:	Patient Phone:		

Urgency:

☐ Standard ☐ Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)

Medication requested:

☐ Tecentriq Hybreza
Other (please specify):

Directions for use: Dose and Quantity: Duration of therapy:

J-Code: ICD10:

Where will this medication be obtained?

☐ Accredo Specialty Pharmacy**
☐ Hospital Outpatient
☐ Retail pharmacy
☐ Other (please specify):
☐ Home Health / Home Infusion vendor
☐ Physician's office stock (billing on a medical claim form)
***Cigna's nationally preferred specialty pharmacy*

***Medication orders can be placed with Accredo via E-prescribe - Accredo (1620 Century Center Pkwy, Memphis, TN 38134-8822 | NCPDP 4436920), Fax 888.302.1028, or Verbal 866.759.1557*

Facility and/or doctor dispensing and administering medication:

Facility Name: State: Tax ID#:
Address (City, State, Zip Code):

Where will this drug be administered?

☐ Patient's Home
☐ Hospital Outpatient
☐ Physician's Office
☐ Other (please specify):

Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient? ☐ Yes ☐ No

Diagnosis related to use:

☐ alveolar soft part sarcoma (ASPS)
☐ hepatocellular carcinoma (HCC)
☐ melanoma
☐ non-small cell lung cancer (NSCLC)
☐ peritoneal mesothelioma
☐ small cell lung cancer (SCLC)
☐ small cell neuroendocrine carcinoma of the cervix (NECC)
☐ Other (please specify):

Clinical Information:

(if ASPS or HCC) Does your patient have unresectable or metastatic disease? ☐ Yes ☐ No

(if HCC) Has your patient received systemic therapy for this diagnosis before requesting this medication? ☐ Yes ☐ No

(if HCC) Is/Will this medication (be)ing used in combination with bevacizumab (Alymsys, Avastin, Mvasi, Zirabev)? ☐ Yes ☐ No

(if melanoma) Does your patient have BRAF V600 mutation-positive disease? ☐ Yes ☐ No

(if melanoma) Does your patient have unresectable or metastatic disease? ☐ Yes ☐ No

(if melanoma) Will this medication be taken in combination with cobimetinib (Cotellic) and vemurafenib (Zelboraf)? ☐ Yes ☐ No

(if SCLC) Does your patient have extensive stage disease (ES-SCLC)? ☐ Yes ☐ No

(if SCLC) Will/Was this medication (be) used in combination with carboplatin and etoposide (Etopophos or Toposar)? ☐ Yes ☐ No

(if SCLC) Is this medication being used as part of first line therapy? ☐ Yes ☐ No

(if NSCLC) Is this medication being used as adjuvant treatment (that is treatment given after the main treatment to reduce the chance of cancer coming back by destroying any remaining cancer cells)? ☐ Yes ☐ No

(if adjuvant treatment of NSCLC) Does the patient have stage II (2) (including IIA or IIB) or stage IIIA (3A) disease? ☐ Yes ☐ No

(if adjuvant treatment of NSCLC) Does the patient have PD-L1 expression on 1% or more of the tumor cells? ☐ Yes ☐ No

(if adjuvant treatment of NSCLC) Is this medication being requested AFTER resection of the tumor and platinum-based chemotherapy (such as carboplatin, cisplatin)? ☐ Yes ☐ No

(if not adjuvant treatment for NSCLC) Does your patient have metastatic disease? ☐ Yes ☐ No

(if metastatic NSCLC) Did your patient have disease progression during or after treatment with platinum-based chemotherapy (like carboplatin, cisplatin)? ☐ Yes ☐ No

(if metastatic NSCLC) Has your patient previously received a systemic immune checkpoint inhibitor (such as Keytruda, Opdivo)? ☐ Yes ☐ No

(if metastatic NSCLC) Does your patient have one of the following gene mutations?
☐ EGFR (epidermal growth factor receptor)-positive
☐ ALK (anaplastic lymphoma kinase)-positive
☐ Testing did not indicate either EGFR mutation- or ALK-positive disease
☐ Molecular testing was not done

(if EGFR-positive) Did your patient have disease progression while on either Tarceva, Gilotrif, Iressa, Tagrisso, or Portrazza? ☐ Yes ☐ No

(if ALK-positive) Did your patient have disease progression while on either Xalkori, Zykadia, or Alecensa? ☐ Yes ☐ No

(if 1st line NSCLC) Does your patient have one of the following gene mutations?
☐ EGFR (epidermal growth factor receptor)-positive
☐ ALK (anaplastic lymphoma kinase)-positive
☐ Testing did not indicate either EGFR mutation- or ALK-positive disease
☐ Molecular testing was not done

(if 1st line NSCLC) Is this medication part of the first-line treatment your patient is receiving for this diagnosis? ☐ Yes ☐ No

(if 1st line NSCLC) Which of the following first-line treatments will your patient be using with this medication?
☐ Avastin (bevacizumab), paclitaxel, and carboplatin
☐ Paclitaxel protein-bound (Abraxane) and carboplatin
☐ Other or using alone

(if 1st line NSCLC) Do your patient's tumors have high PD-L1 expression (PD-L1 stained greater than or equal to 50% of tumor cells [TC greater than or equal to 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering greater than or equal to 10% of the tumor area [IC greater than or equal to 10%])? ☐ Yes ☐ No

(if NECC) Does your patient have persistent, recurrent or metastatic disease? ☐ Yes ☐ No

(if NECC) Is/Will this medication (be)ing used in combination with cisplatin or carboplatin and etoposide? ☐ Yes ☐ No

(if NECC) Will this medication be continued as a single agent for maintenance therapy? ☐ Yes ☐ No

(if peritoneal mesothelioma) Is this medication being used for first-line systemic therapy or subsequent (after first-line) systemic therapy?
☐ First-line systemic therapy
☐ Subsequent systemic therapy
☐ Unknown

(if peritoneal mesothelioma) What is your patient's ECOG performance status (PS)?
☐ PS 0
☐ PS 1
☐ PS 2
☐ PS 3
☐ PS 4
☐ Unknown

(if peritoneal mesothelioma) Is/Will this medication (be)ing used in combination with bevacizumab (Alymsys, Avastin, Mvasi, Zirabev)?
☐ Yes ☐ No

(if peritoneal mesothelioma) Has your patient previously received a systemic immune checkpoint inhibitor (such as Keytruda, Opdivo)?
☐ Yes ☐ No

Additional Pertinent Information: *(including disease stage, prior therapy, performance status, and names/doses/admin schedule of any agents to be used concurrently):*

Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature:_____ **Date:**_____

Save Time! Submit Online at: www.covermymeds.com/main/prior-authorization-forms/cigna/ or via SureScripts in your EHR.

Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cigna.com.

v020125

"Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005